← Leaderboards
Stefan Zauscher
Duke University
$1,908,306
Attributed
$2,789,018
Total exposure
3
Grants
2
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $611.9K · FY2012–25$1M$750K$500K$250K$0
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$2,789,018 · 3
By mechanism
R01$1,761,424 · 1
R21$1,027,594 · 2
Top collaborators
- Shyni Varghese3 shared
Most similar at Duke University
Same institution · by research overlap
- Ashutosh Chilkoti$32,367,884
- Gregory E Crawford$24,798,952
- Krishnendu Chakrabarty$6,360,706
- Joseph F Costello$28,805,991
- Charles A Gersbach$24,146,412
Others in their field
Top investigators on “Molecular”
- David Heimbrook · Leidos Biomedical Research, Inc.$871,088,761
- Leonard Freedman · Leidos Biomedical Research, Inc.$468,573,385
- Richard Webby · St. Jude Children'S Research Hospital$254,843,170
- Larry Arthur$238,531,074
- Gregory H Reaman · National Childhood Cancer Foundation$230,630,913
- Ralph Parchment · Leidos Biomedical Research, Inc.$193,231,914
Research focus
MolecularDesignClinicArchitectureIn VivoLiquid SubstanceAtomic Force MicroscopyMeasurementSurfacePropertyEngineeringAdhesionsLipidsPositioning AttributeAdhesivesAnimal ModelCancer CellAnti-Cancer TherapeuticAnalogBone TissueCancer TherapyBenchmarkingAnti-CancerBase
Grant awards (8)
Molecular engineering of HA-based lubricants for articular cartilage$567,773
R01 · FY2025 · AR
Molecular engineering of HA-based lubricants for articular cartilage$581,707
R01 · FY2024 · AR
Molecular engineering of HA-based lubricants for articular cartilage$611,944
R01 · FY2023 · AR
In situ Enzymatic Synthesis of Aptamer Targeted Polynucleotide Drug Nanoparticles for Cancer Therapy$193,694
R21 · FY2020 · EB · contact PI
In situ Enzymatic Synthesis of Aptamer Targeted Polynucleotide Drug Nanoparticles for Cancer Therapy$233,612
R21 · FY2019 · EB · contact PI
In situ Enzymatic Synthesis of Aptamer Targeted Polynucleotide Drug Nanoparticles for Cancer Therapy$193,258
R21 · FY2018 · EB · contact PI
HIV-1 Neutralizing Antibody Binding to Viral Membrane Mimics$177,360
R21 · FY2013 · AI · contact PI
HIV-1 Neutralizing Antibody Binding to Viral Membrane Mimics$229,670
R21 · FY2012 · AI · contact PI